Mymetics Corporation (MYMX) Research

Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent. Additionally, Mymetics works with Sanofi Pasteur Biologics, LLC to assess the immunogenicity of influenza vaccines. Founded in 1990, the company was formerly known as ICHOR Corporation, adopting its current name in July 2001, and maintains its base of operations in Epalinges, Switzerland.

Market snapshot

Symbol
MYMX
Price
$0.00
Day change
0.00%
Market cap
$40.1
P/E ratio
-0.02x
52-week range
0.0003-0.0003
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Acusphere, Inc. (ACUS)
  • American Oriental Bioengineering, Inc. (AOBI)
  • Aspyra Inc. (APYI)
  • Cardax, Inc. (CDXI)
  • Islet Holdings, Inc. (ISHI)
  • Cannabiz Mobile, Inc. (LGBI)
  • NexImmune, Inc. (NEXI)
  • Nobilis Health Corp. (NRTSF)

Recent insider activity

  • KEMPERS Ronald Hugo Gerard — A-Award (5000000 shares) on 2015-04-09
  • Round Enterprises, Ltd. — trade (0 shares) on 2006-01-31
  • Round Enterprises, Ltd. — trade (0 shares) on 2006-01-31
  • Fleury Sylvain — A-Award (800000 shares) on 2013-10-04
  • Fleury Sylvain — A-Award (350000 shares) on 2009-12-31

Open Mymetics Corporation (MYMX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.